ReproCELL Incorporated (TSE: 4978)
Health Care · Biotechnology · JP
¥130.00
-1.52% today · -25.7% 1Y
ReproCELL Incorporated (TSE: 4978) operates in the Biotechnology industry within the Health Care sector. The company is valued at $85.24M and employs 101 people.
Over the last twelve months the share price has lost 25.7%, trading between 117.00 and 204.00.
Tweenvest scores ReproCELL Incorporated across four factors: quality 59/100, value 41/100, growth 58/100. Its strongest factor is quality.
4978 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $85.24M
- Revenue (TTM)
- $14.17M
- P/E
- —
- EPS
- -4.59
- Dividend yield
- —
- Beta (5Y)
- 0.54
- 52-week high
- ¥204.00
- 52-week low
- ¥117.00
- Avg volume (3M)
- —
- Shares outstanding
- 103.83M
- Employees
- 101
- Next earnings
- —
About ReproCELL Incorporated
Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.
- ISIN
- JP3974770004
- Founded
- 2003
- Listed since
- Jun 26, 2013
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Revium Rx.OTCPK: RVRC | $86.84M | $— | — |
| Quantum Cyber N.V.NasdaqCM: QUCY | $86.59M | $1.06 | +2.91% |
| Devyser Diagnostics AB (publ)OM: DVYSR | $85.81M | Skr50.80 | 0.00% |
| AnGes, Inc.TSE: 4563 | $85.64M | ¥34.00 | -2.86% |
| ProMIS Neurosciences, Inc.NasdaqCM: PMN | $84.74M | $8.65 | -8.47% |
| BIOTON S.A.WSE: BIO | $84.38M | zł3.80 | -1.30% |
| Allied Biotech CorporationTPEX: 1780 | $84.09M | NT$24.65 | -2.76% |
| Cardiff Oncology, Inc.NasdaqCM: CRDF | $84.02M | $1.02 | -5.56% |
Figures last refreshed Oct 11, 2026.